In vitro antibacterial activities of tigecycline in combination with 5 antimicrobial agents for Stenotrophomonas maltophilia determined by broth microdilution method and chequerboard

doi:10.3969/j.issn.1006-7795.2021.04.018

Abstract

Abstract: Objective To investigate the In vitro antibacterial activities of tigecycline combined with levofloxacin, sulfamethoxazole-trimethoprim(SXT), minocycline, ceftazidime, cefperazone-sulbactam for Stenotrophomonas maltophilia (SMA) isolates resistant to levofloxacin. Methods Totally 33 SMA isolates resistant to levofloxacin were cultured from patients with bacteremia and tissue infection and collected from Beijing Friendship Hospital, Capital Medical University. All SMA isolates were divided into 3 groups: levofloxacin resistant isolates(n=17); levofloxacin resistant, SXT resistant isolates(n=11);levofloxacin resistant, SXT resistant, minocycline resistant isolates(n=5). The susceptibility of 6 agents against these SMA were tested by broth microdilution method. Tigecycline combined with levofloxacin, sulfamethoxazole-trimethoprim(SXT), minocycline, ceftazidime, cefperazone-sulbactam against these isolates were performed by chequerboard dilution. The fractional inhibitory concentration (FIC) index was calculated to evaluate the efficiency of these combination. Results Susceptibilities of tigecycline to levofloxacin resistant SMA and levofloxacin resistant, SXT resistant SMA were 76.4% and 54.5%, respectively, and it's a bit lower than susceptibilities of minocycline. According to the results of chequerboard, the combination of tigecycline with levofloxacin, ceftazidime, cefperazone-sulbactam showed synergy against some SMA isolates. None of the combinations showed antagonistic activity. Conclusions Tigecycline combined with levofloxacin, ceftazidime or cefperazone-sulbactam may be a choice for treating SMA infection in clinical practice.

Key words: tigecycline, Stenotrophomonas maltophilia, broth microdilution method, chequerboard dilution

CLC Number:

R446.5

Wei Jingjuan, Ma Liyan, Su Jianrong. In vitro antibacterial activities of tigecycline in combination with 5 antimicrobial agents for Stenotrophomonas maltophilia determined by broth microdilution method and chequerboard[J]. Journal of Capital Medical University, 2021, 42(4): 623-628.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2021.04.018

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2021/V42/I4/623

References

[1] Lodise T P, Echols R, Wang W, et al. Prevalence and microbiology of carbapenem resistance among six gram-negative pathogens in bloodstream infections in US hospitals, 2010-2015[J]. Open Forum Infect Dis, 2018, 5:S360.
[2] Adegoke A A, Stenstrom T A, Okoh A I. Stenotrophomonas maltophilia as an emerging ubiquitous pathogen: looking beyond contemporary antibiotic therapy[J]. Front Microbiol, 2017, 8:2276.
[3] Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing[S].2020, M100-S30.
[4] 中国医疗保健国际交流促进会临床微生物与感染分会, 中华医学会检验医学分会临床微生物学组, 中华医学会微生物学与免疫学分会临床微生物学组. 多黏菌素类与替加环素及头孢他啶/阿维巴坦药敏方法和报告专家共识[J]. 中华检验医学杂志, 2020, 43(10): 964-972.
[5] Tangdiin T,Hickman R A,Forsberg P, et al. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments[J]. Antimicrob Agents Chemother,2014, 58(3):1757-1762.
[6] Chang Y T,Lin C Y,Chen Y H, et al. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options[J]. Front Microbiol, 2015, 6:893.
[7] 秦立霞,李芳,赵会海.感染性无菌体液细菌分布及耐药性分析[J].临床误诊误治,2020,33(3):77-82.
[8] 付黎明,朱平.雾化吸入阿米卡星对治疗老年重症社区获得性肺炎的疗效观察[J].首都医科大学学报,2018,39(3):428-432.
[9] 赵鹏英,宋兵.风湿性瓣膜病合并嗜麦芽窄食单胞菌感染性心内膜炎1例[J].心肺血管病杂志,2018,37(10):940-941.
[10] 段忠亮,秦娟秀,李敏, 等. 上海某医院临床分离嗜麦芽窄食单胞菌分子流行病学分析[J]. 中国感染与化疗杂志,2017,17(3):283-288.
[11] Hu L F, Xu X H, Li H R, et al. Surveillance of antimicrobial susceptibility patterns among Stenotrophomonas maltophilia isolated in China during the 10-year period of 2005-2014[J]. J Chemother, 2018,30(1):25-30.
[12] Farrell D J, Sader H S, Jones R N. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections[J]. Antimicrob Agents Chemother, 2010, 54(6):2735-2737.
[13] Hand E, Davis H, Kim T, et al. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections[J]. J Antimicrob Chemother, 2016, 71(4):1071-1075.
[14] Bostanghadiri N, Ghalavand Z, Fallah F, et al. Characterization of phenotypic and genotypic diversity of Stenotrophomonas maltophilia strains isolated from selected hospitals in Iran[J]. Front Microbiol, 2019, 10:1191.
[15] Watson L, Esterly J, Jensen A O, et al. Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections[J]. J Glob Antimicrob Resist, 2018, 12:104-106.
[16] Nys C, Cherabuddi K, Venugopalan V, et al. Clinical and microbiologic outcomes in patients with monomicrobial Stenotrophomonas maltophilia infections[J]. Antimicrob Agents Chemother, 2019, 63(11):e00788-19.
[17] Pfaller M A, Huband M D, Shortridge D, et al. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY Antimicrobial Surveillance Program[J]. Antimicrob Agents Chemother, 2018, 62(4): e02327-17.
[18] Rizek C,Ferraz J R,van der Heijden I M,et al. In vitro activity of potential old and new drugs against multidrag-resistant gram-negatives[J]. J Infect Chemother, 2015, 21(2):114-117.
[19] Biagi M, Tan X, Wu T, et al. Activity of potential alternative treatment agents for stenotrophomonas maltophilia isolates nonsusceptible to levofloxacin and/or trimethoprim-sulfamethoxazole[J]. J Clin Microbiol, 2020, 58(2):e01603-19.
[20] Nicodemo A C, Paez J I. Antimicrobial therapy for Stenotrophomonas maltophilia infections[J]. Eur J Clin Microbiol Infect Dis, 2007,26(4): 229-237.
[21] Karamanlioğlu D, Dizbay M. In vitro combination of tigecycline with other antibiotics in Stenotrophomonas maltophilia isolates[J]. Turk J Med Sci, 2019,49(2): 683-686.